Oncogenic KRAS-Driven Metabolic Reprogramming in Pancreatic Cancer Cells Utilizes Cytokines from the Tumor Microenvironment
Published version of a preprint
Abstract
A hallmark of pancreatic ductal adenocarcinoma (PDAC) is an exuberant stroma comprised of diverse cell types that enable or suppress tumor progression. Here, we explored the role of oncogenic KRAS in protumorigenic signaling interactions between cancer cells and host cells. We show that KRAS mutation (KRAS*) drives cell-autonomous expression of type I cytokine receptor complexes (IL2rγ–IL4rα and IL2rγ–IL13rα1) in cancer cells that in turn are capable of receiving cytokine growth signals (IL4 or IL13) provided by invading Th2 cells in the microenvironment. Early neoplastic lesions show close proximity of cancer cells harboring KRAS* and Th2 cells producing IL4 and IL13. Activated IL2rγ–IL4rα and IL2rγ–IL13rα1 receptors signal primarily via JAK1–STAT6. Integrated transcriptomic, chromatin occupancy, and metabolomic studies identified MYC as a direct target of activated STAT6 and that MYC drives glycolysis. Thus, paracrine signaling in the tumor microenvironment plays a key role in the KRAS*-driven metabolic reprogramming of PDAC. Significance: Type II cytokines, secreted by Th2 cells in the tumor microenvironment, can stimulate cancer cell–intrinsic MYC transcriptional upregulation to drive glycolysis. This KRAS*-driven heterotypic signaling circuit in the early and advanced tumor microenvironment enables cooperative protumorigenic interactions, providing candidate therapeutic targets in the KRAS* pathway for this intractable disease.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In KRASG12D-driven PDAC mouse models, immune suppressive cytokines IL-4 and IL-13 and remodeling of myeloid cell composition in the tumor microenvironment have been demonstrated.
“In a KRASG12D mutation driven PDAC mice model, immune suppressive cytokines IL-4 and IL-13 and remodeling of the myeloid cell composition in TME have been demonstrated40,41.”
From Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma (2024) · cites this paper as [41]
Cites
Fast gapped-read alignment with Bowtie 2
Langmead, B., & Salzberg, S. L. (2012) · Nature Methods · doi:10.1038/nmeth.1923 · Cited by 56,400 · see citing works
Trapnell, C., Roberts, A., Goff, L. A., Pertea, G. M., Kim, D., Kelley, D. R., Pimentel, H., Salzberg, S. L., Rinn, J. L., & Pachter, L. S. (2012) · Nature Protocols · doi:10.1038/nprot.2012.016 · Cited by 11,930 · see citing works
Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche
Sato, T., Vries, R. G., Snippert, H. J., van de Wetering, M., Barker, N., Stange, D. E., van Es, J. H., Abo, A., Kujala, P., Peters, P. J., et al. (2009) · Nature · doi:10.1038/nature07935 · Cited by 7,204 · see citing works
Dang, C. V. (2012) · Cell · doi:10.1016/j.cell.2012.03.003 · Cited by 3,390 · see citing works
Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism
Ying, H., Kimmelman, A. C., Lyssiotis, C. A., Hua, S., Chu, G. C., Fletcher-Sananikone, E., Locasale, J. W., Son, J., Zhang, H., Coloff, J. L., et al. (2012) · Cell · doi:10.1016/j.cell.2012.01.058 · Cited by 2,043 · see citing works
Self-citationGlutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway
Son, J., Lyssiotis, C. A., Ying, H., Wang, X., Hua, S., Ligorio, M., Perera, R. M., Ferrone, C. R., Mullarky, E., Shyh-Chang, N., et al. (2013) · Nature · doi:10.1038/nature12040 · Cited by 1,990 · see citing works
Self-citationChronic inflammation and cytokines in the tumor microenvironment
Landskron, G., De la Fuente, M., Thuwajit, P., Thuwajit, C., & Hermoso, M. A. (2014) · Journal of Immunology Research · doi:10.1155/2014/149185 · Cited by 1,765 · see citing works
Genetics and biology of pancreatic ductal adenocarcinomaPreprint
Hezel, A. F., Kimmelman, A. C., Stanger, B. Z., Bardeesy, N. M., & DePinho, R. A. (2006) · Genes & Development · doi:10.1101/gad.1415606 · Cited by 1,570 · see citing works
Self-citationCytokines in cancer pathogenesis and cancer therapy
Dranoff, G. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1252 · Cited by 1,567 · see citing works
Amir, E.-A. D., Davis, K. L., Tadmor, M. D., Simonds, E. F., Levine, J. H., Bendall, S. C., Shenfeld, D. K., Krishnaswamy, S., Nolan, G. P., & Pe'er, D. (2013) · Nature Biotechnology · doi:10.1038/nbt.2594 · Cited by 1,550 · see citing works
DeNardo, D. G., Barreto, J., Andreu, P., Vásquez, L. J., Tawfik, D., Kolhatkar, N. S., & Coussens, L. M. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.06.018 · Cited by 1,340 · see citing works
The Pancreas Cancer Microenvironment
Feig, C., Gopinathan, A., Neesse, A., Chan, D. S., Cook, N., & Tuveson, D. A. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3114 · Cited by 1,316 · see citing works
Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function
Viale, A., Pettazzoni, P., Lyssiotis, C. A., Ying, H., Sánchez, N., Marchesini, M., Carugo, A., Green, T., Seth, S., Giuliani, V., et al. (2014) · Nature · doi:10.1038/nature13611 · Cited by 1,259 · see citing works
Self-citationNeutralizing Tumor-Promoting Chronic Inflammation: A Magic Bullet?
Coussens, L. M., Zitvogel, L., & Palucka, A. K. (2013) · Science · doi:10.1126/science.1232227 · Cited by 1,070 · see citing works
Aguirre, A. J., Bardeesy, N., Sinha, M., Lopez, L., Tuveson, D. A., Horner, J., Redston, M. S., & DePinho, R. A. (2003) · Genes & Development · doi:10.1101/gad.1158703 · Cited by 1,033 · cited 2× · see citing works
“Primary mouse cell lines were established in the laboratory (AK-B6, AK192, HY6468, PJAK4217, PJAK4298) as described previously (34) and were routinely cultured in RPMI 1640 (Invitrogen) 10% FBS (Invitrogen).”
MethodSelf-citationDynamics of the immune reaction to pancreatic cancer from inception to invasion
Clark, C. E., Hingorani, S. R., Mick, R., Combs, C., Tuveson, D. A., & Vonderheide, R. H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0175 · Cited by 990 · see citing works
Bayne, L. J., Beatty, G. L., Jhala, N., Clark, C. E., Rhim, A. D., Stanger, B. Z., & Vonderheide, R. H. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.04.025 · Cited by 947 · cited 1× · see citing works
“, have been long associated with the recruitment of leukocytes into the TME, which creates a tumor-permissive niche for cancer cells to thrive (43, 44).”
BackgroundJAKs and STATs in immunity, immunodeficiency, and cancer
O'Shea, J. J., Holland, S. M., & Staudt, L. M. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1202117 · Cited by 927 · see citing works
Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer
Ino, Y., Yamazaki–Itoh, R., Shimada, K., Iwasaki, M., Kosuge, T., Kanai, Y., & Hiraoka, N. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.32 · Cited by 853 · see citing works
Environment impacts the metabolic dependencies of Ras-driven non-small cell lung cancer
Davidson, S. M., Papagiannakopoulos, T., Olenchock, B. A., Heyman, J. E., Keibler, M. A., Luengo, A., Bauer, M. R., Jha, A. K., O’Brien, J. P., Pierce, K. A., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.01.007 · Cited by 737 · see citing works
Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia
Pylayeva-Gupta, Y., Lee, K. E., Hajdu, C. H., Miller, G., & Bar-Sagi, D. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.04.024 · Cited by 721 · see citing works
Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer
Kapoor, A., Yao, W., Ying, H., Hua, S., Liewen, A., Wang, Q., Zhong, Y., Wu, C.-J., Sadanandam, A., Hu, B., et al. (2014) · Cell · doi:10.1016/j.cell.2014.06.003 · Cited by 716 · cited 6× · see citing works
“On the basis of these findings, we speculated that infiltrating Th2 cells Cytokines Mediated Tumor Progression in PDAC RESEARCH ARTICLE APRIL 2020 CANCER DISCOVERY | 617 Murine T cells are predominantly CD4+ type Analysis of T-cell infiltration (iMC) GATA3+CD4+ T cells infiltrate murine PanIN Pdx1-Cre;LSL-KrasG12D scR…”
BackgroundInfluentialSelf-citationMonte, L. B. D., Reni, M., Tassi, E., Clavenna, D., Papa, I., Recalde, H. R., Braga, M., Carlo, V. D., Doglioni, C., & Protti, M. P. (2011) · The Journal of Experimental Medicine · doi:10.1084/jem.20101876 · Cited by 692 · see citing works
Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells
Yuneva, M., Zamboni, N., Oefner, P., Sachidanandam, R., & Lazebnik, Y. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200703099 · Cited by 690 · see citing works
Hosios, A. M., Hecht, V. C., Danai, L. V., Johnson, M. O., Rathmell, J. C., Steinhauser, M. L., Manalis, S. R., & Vander Heiden, M. G. (2016) · Developmental Cell · doi:10.1016/j.devcel.2016.02.012 · Cited by 641 · see citing works
Carstens, J. L., Correa de Sampaio, P., Yang, D., Barua, S., Wang, H., Rao, A., Allison, J. P., LeBleu, V. S., & Kalluri, R. (2017) · Nature Communications · doi:10.1038/ncomms15095 · Cited by 633 · see citing works
Self-citationMYC, Metabolism, Cell Growth, and TumorigenesisPreprint
Dang, C. V. (2013) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a014217 · Cited by 600 · see citing works
Tissue of origin dictates branched-chain amino acid metabolism in mutant <i>Kras</i> -driven cancers
Mayers, J. R., Torrence, M. E., Danai, L. V., Papagiannakopoulos, T., Davidson, S. M., Bauer, M. R., Lau, A. N., Ji, B. W., Dixit, P. D., Hosios, A. M., et al. (2016) · Science · doi:10.1126/science.aaf5171 · Cited by 582 · see citing works
Functional role for c-myc in mitogenic response to platelet-derived growth factor
Armelin, H. A., Armelin, M. C. S., Kelly, K., Stewart, T. A., Leder, P., Cochran, B., & Stiles, C. D. (1984) · Nature · doi:10.1038/310655a0 · Cited by 565 · see citing works
Cutting Edge: The Common γ-Chain Is an Indispensable Subunit of the IL-21 Receptor Complex
Asao, H., Okuyama, C., Kumaki, S., Ishii, N., Tsuchiya, S., Foster, D., & Sugamura, K. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.1.1 · Cited by 540 · see citing works
Genetics and biology of pancreatic ductal adenocarcinoma
Ying, H., Dey, P., Yao, W., Kimmelman, A. C., Draetta, G. F., Maitra, A., & DePinho, R. A. (2016) · Genes & Development · doi:10.1101/gad.275776.115 · Cited by 527 · see citing works
Self-citationMcAllister, F., Bailey, J. M., Alsina, J., Nirschl, C. J., Sharma, R., Fan, H., Rattigan, Y., Roeser, J. C., Lankapalli, R. H., Zhang, H., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.03.014 · Cited by 405 · see citing works
Self-citationBernard, V., Semaan, A., Huang, J. H., Lucas, F. A. S., Mulu, F. C., Stephens, B. M., Guerrero, P. A., Huang, Y., Zhao, J., Kamyabi, N., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1955 · Cited by 387 · see citing works
Self-citationBlando, J., Sharma, A., Higa, M. G., Zhao, H., Vence, L., Yadav, S. S., Kim, J., Sepulveda, A. M., Sharp, M., Maitra, A., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1811067116 · Cited by 334 · see citing works
Self-citationDirect evidence for cancer-cell-autonomous extracellular protein catabolism in pancreatic tumors
Davidson, S. M., Jonas, O., Keibler, M. A., Hou, H. W., Luengo, A., Mayers, J. R., Wyckoff, J., Del Rosario, A. M., Whitman, M., Chin, C. R., et al. (2017) · Nature Medicine · doi:10.1038/nm.4256 · Cited by 331 · see citing works
The differential expression of IL-4 and IL-13 and its impact on type-2 immunity
Bao, K., & Reinhardt, R. L. (2015) · Cytokine · doi:10.1016/j.cyto.2015.05.008 · Cited by 316 · see citing works
A unique glucose-dependent apoptotic pathway induced by c-Myc
Shim, H., Chun, Y. S., Lewis, B. C., & Dang, C. V. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.4.1511 · Cited by 286 · see citing works
The functional plasticity of T cell subsets
Bluestone, J. A., Mackay, C. R., O’Shea, J. J., & Stockinger, B. (2009) · Nature reviews. Immunology · doi:10.1038/nri2654 · Cited by 285 · see citing works
Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer
Dey, P., Baddour, J., Muller, F., Wu, C. C., Wang, H., Liao, W.-T., Lan, Z., Chen, A., Gutschner, T., Kang, Y., et al. (2017) · Nature · doi:10.1038/nature21052 · Cited by 264 · see citing works
Self-citationRole of IL-13 in regulation of anti-tumor immunity and tumor growth
Terabe, M., Park, J. M., & Berzofsky, J. A. (2003) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-003-0445-0 · Cited by 210 · see citing works
Inflammatory networks and immune surveillance of pancreatic carcinoma
Vonderheide, R. H., & Bayne, L. J. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2013.01.006 · Cited by 200 · see citing works
KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory Mechanism
Vaseva, A. V., Blake, D. R., Gilbert, T. S. K., Ng, S., Hostetter, G. H., Azam, S. H., Ozkan‐Dagliyan, I., Gautam, P., Bryant, K. L., Pearce, K. H., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.10.001 · Cited by 181 · see citing works
Alternative activation of tumor-associated macrophages by IL-4
Wang, H., & Joyce, J. A. (2010) · Cell Cycle · doi:10.4161/cc.9.24.14322 · Cited by 177 · see citing works
Self-citationSurvival of pancreatic cancer cells lacking KRAS function
Muzumdar, M. D., Chen, P.-Y., Dorans, K. J., Chung, K. M., Bhutkar, A., Hong, E., Noll, E. M., Sprick, M. R., Trumpp, A., & Jacks, T. (2017) · Nature Communications · doi:10.1038/s41467-017-00942-5 · Cited by 177 · see citing works
c-Myc depletion inhibits proliferation of human tumor cells at various stages of the cell cycle
Wang, H., Mannava, S., Grachtchouk, V., Zhuang, D., Soengas, M. S., Gudkov, A. V., Prochownik, E. V., & Nikiforov, M. A. (2007) · Oncogene · doi:10.1038/sj.onc.1210823 · Cited by 174 · see citing works
Self-citationZhang, Y., Zoltan, M. A., Riquelme, E. M., Xu, H., Şahin, İ., Castro-Pando, S., Montiel, M. F., Chang, K., Jiang, Z., Ling, J., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.03.041 · Cited by 152 · see citing works
Self-citationStromal cues regulate the pancreatic cancer epigenome and metabolome
Sherman, M. H., Yu, R. T., Tseng, T. W., Sousa, C. M., Liu, S., Truitt, M. L., He, N., Ding, N., Liddle, C., Atkins, A. R., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1620164114 · Cited by 147 · see citing works
Koh, C. M., Gürel, B., Sutcliffe, S. S., Aryee, M. J., Schultz, D., Iwata, T., Uemura, M., Zeller, K. I., Anele, U. A., Zheng, Q., et al. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2010.12.040 · Cited by 133 · see citing works
IL-4: role in disease and regulation of production
Choi, P., & Reiser, H. (1998) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.1998.00690.x · Cited by 131 · see citing works
Dey, P., Ström, A., & Gustafsson, J.-Å. (2013) · Oncogene · doi:10.1038/onc.2013.384 · Cited by 113 · see citing works
Self-citationHurwitz, H. I., Cutsem, E. V., Bendell, J. C., Hidalgo, M. M., Li, C., Salvo, M. G., Macarulla, T. M., Sahai, V., Sama, A. R., Greeno, E. W., et al. (2018) · Investigational New Drugs · doi:10.1007/s10637-018-0580-2 · Cited by 113 · see citing works
Novel c‐MYC target genes mediate differential effects on cell proliferation and migration
Cappellen, D., Schlange, T., Bauer, M., Maurer, F., & Hynes, N. E. (2006) · EMBO Reports · doi:10.1038/sj.embor.7400849 · Cited by 110 · see citing works
Dey, P., Jonsson, P., Hartman, J., Williams, C., Ström, A., & Gustafsson, J.-Α. (2012) · Molecular Endocrinology · doi:10.1210/me.2012.1227 · Cited by 110 · see citing works
Self-citationTargeting IL4/IL4R for the treatment of epithelial cancer metastasis
Venmar, K. T., & Fingleton, B. (2015) · Clinical & Experimental Metastasis · doi:10.1007/s10585-015-9747-9 · Cited by 95 · see citing works
Immune infiltrates as predictive markers of survival in pancreatic cancer patients
Protti, M. P., & Monte, L. B. D. (2013) · Frontiers in Physiology · doi:10.3389/fphys.2013.00210 · Cited by 91 · see citing works
Exploiting inflammation for therapeutic gain in pancreatic cancer
Steele, C. W., Jamieson, N. B., Evans, T. R. J., McKay, C. J., Sansom, O. J., Morton, J. P., & Carter, C. R. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.24 · Cited by 77 · see citing works
Rajamani, D., & Bhasin, M. (2016) · Genome Medicine · doi:10.1186/s13073-016-0282-3 · Cited by 70 · see citing works
Control of Cell Proliferation and Growth by Myc Proteins
Bernard, S., & Eilers, M. (2006) · Springer eBooks · doi:10.1007/400_004 · Cited by 47 · see citing works
Mikhalkevich, N., Becknell, B., Caligiuri, M. A., Bates, M. D., Harvey, R. P., & Zheng, W.-P. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.3.1553 · Cited by 40 · see citing works
Dose-dependent regulation of target gene expression and cell proliferation by c-Myc levels
Schuhmacher, M., & Eick, D. (2013) · Transcription · doi:10.4161/trns.25907 · Cited by 38 · see citing works
Dose and context dependent effects of Myc on epidermal stem cell proliferation and differentiation
Berta, M., Baker, C. M., Cottle, D. L., & Watt, F. M. (2009) · EMBO Molecular Medicine · doi:10.1002/emmm.200900047 · Cited by 33 · see citing works
Eagar, T. N., Turley, D. M., Padilla, J., Karandikar, N. J., Tan, L., Bluestone, J. A., & Miller, S. D. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.12.7442 · Cited by 32 · see citing works
The role of the common gamma-chain family cytokines in γδ T cell-based anti-cancer immunotherapy
Acker, H. H. V., Campillo-Davó, D., Roex, G., Versteven, M., Smits, E., & Tendeloo, V. F. V. (2018) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2018.05.002 · Cited by 25 · see citing works
CTLA‐4 Engagement Inhibits Th2 but not Th1 Cell Polarisation
Ubaldi, V., Gatta, L., Pace, L., Doria, G., & Pioli, C. (2003) · Journal of Immunology Research · doi:10.1080/10446670310001598519 · Cited by 24 · see citing works
Ayars, M., O’Sullivan, E., Macgregor‐Das, A. M., Shindo, K., Kim, H., Borges, M. W., Yu, J., Hruban, R. H., & Goggins, M. (2017) · Oncotarget · doi:10.18632/oncotarget.19848 · Cited by 23 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Cold and hot tumors: from molecular mechanisms to targeted therapy
Wu, B., Zhang, B., Li, B., Wu, H., & Jiang, M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01979-x · Cited by 751 · see citing works
Fungal mycobiome drives IL-33 secretion and type 2 immunity in pancreatic cancer
Alam, A., Levanduski, E., Denz, P. J., Villavicencio, H. S., Bhatta, M., Alhorebi, L., Zhang, Y., Gomez, E. C., Morreale, B. G., Senchanthisai, S., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.01.003 · Cited by 374 · see citing works
Self-citationCell death in pancreatic cancer: from pathogenesis to therapy
Chen, X., Zeh, H. J., Kang, R., Kroemer, G., & Tang, D. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00486-6 · Cited by 338 · see citing works
Metabolic Codependencies in the Tumor Microenvironment
Dey, P., Kimmelman, A. C., & DePinho, R. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1211 · Cited by 342 · see citing works
Self-citationSTAT proteins in cancer: orchestration of metabolism
Li, Y., Zhang, C., Martincuks, A., Herrmann, A., & Yu, H. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-022-00537-3 · Cited by 287 · see citing works
Mahadevan, K. K., McAndrews, K. M., LeBleu, V. S., Yang, S., Lyu, H., Li, B., Sockwell, A. M., Kirtley, M. L., Morse, S. J., Moreno Diaz, B. A., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.07.002 · Cited by 258 · see citing works
Self-citationCancer Stemness Meets Immunity: From Mechanism to Therapy
Chen, P., Hsu, W., Han, J., Xia, Y., & DePinho, R. A. (2021) · Cell Reports · doi:10.1016/j.celrep.2020.108597 · Cited by 251 · see citing works
Self-citationMetabolic networks in mutant KRAS-driven tumours: tissue specificities and the microenvironment
Kerk, S. A., Papagiannakopoulos, T. Y., Shah, Y. M., & Lyssiotis, C. A. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00375-9 · Cited by 238 · see citing works
Regulation and modulation of antitumor immunity in pancreatic cancer
Leinwand, J., & Miller, G. (2020) · Nature Immunology · doi:10.1038/s41590-020-0761-y · Cited by 205 · see citing works
Context-Specific Determinants of the Immunosuppressive Tumor Microenvironment in Pancreatic Cancer
Falcomatà, C., Bärthel, S., Schneider, G., Rad, R., Schmidt‐Supprian, M., & Saur, D. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0876 · Cited by 213 · see citing works
Muthalagu, N., Monteverde, T., Raffo-Iraolagoitia, X., Wiesheu, R., Whyte, D., Hedley, A., Laing, S., Kruspig, B., Upstill-Goddard, R., Shaw, R., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0620 · Cited by 182 · see citing works
Harnessing metabolic dependencies in pancreatic cancers
Encarnación-Rosado, J., & Kimmelman, A. C. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00431-7 · Cited by 180 · see citing works
Tumor Microenvironment Remodeling Enables Bypass of Oncogenic KRAS Dependency in Pancreatic Cancer
Hou, P., Kapoor, A., Zhang, Q., Li, J., Wu, C.-J., Li, J., Lan, Z., Tang, M., Ma, X., Ackroyd, J. J., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0597 · Cited by 154 · see citing works
Self-citationKRAS(G12D) can be targeted by potent inhibitors via formation of salt bridge
Mao, Z., Xiao, H., Shen, P., Yang, Y., Xue, J., Yang, Y., Shang, Y., Zhang, L., Li, X., Zhang, Y., et al. (2022) · Cell Discovery · doi:10.1038/s41421-021-00368-w · Cited by 158 · see citing works
A Small Molecule with Big Impact: MRTX1133 Targets the KRASG12D Mutation in Pancreatic Cancer
Wei, D., Wang, L., Zuo, X., Maitra, A., & Bresalier, R. S. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-2098 · Cited by 163 · see citing works
Self-citationKRAS G12D targeted therapies for pancreatic cancer: Has the fortress been conquered?
Bannoura, S. F., Khan, H. Y., & Azmi, A. S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1013902 · Cited by 122 · see citing works
Nielsen, S. R., Strøbech, J. E., Horton, E. R., Jackstadt, R., Laitala, A., Bravo, M. C., Maltese, G., Jensen, A. R. D., Reuten, R., Rafaeva, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23731-7 · Cited by 119 · see citing works
Karpathiou, G., Papoudou-Bai, A., Ferrand, E., Dumollard, J. M., & Peoc’h, M. (2021) · Pathology - Research and Practice · doi:10.1016/j.prp.2021.153477 · Cited by 116 · see citing works
Epithelial and stromal co-evolution and complicity in pancreatic cancer
Hingorani, S. R. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00530-w · Cited by 108 · see citing works
Chen, H., Zhang, C., Wang, H., & Zhao, L. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1887552 · Cited by 111 · see citing works
Self-citationTargeting KRAS in pancreatic cancer: new drugs on the horizon
Bannoura, S. F., Uddin, M. H., Nagasaka, M., Fazili, F., Hallak, M. N. A., Philip, P. A., El‐Rayes, B. F., & Azmi, A. S. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-09990-2 · Cited by 105 · see citing works
Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma
Yousef, A., Yousef, M., Chowdhury, S., Abdilleh, K., Knafl, M., Edelkamp, P., Alfaro-Munoz, K., Chacko, R., Peterson, J., Smaglo, B. G., et al. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00505-0 · Cited by 93 · see citing works
Self-citationThe roles of KRAS in cancer metabolism, tumor microenvironment and clinical therapy
Ma, Q., Zhang, W., Wu, K., & Shi, L. (2025) · Molecular Cancer · doi:10.1186/s12943-024-02218-1 · Cited by 88 · see citing works
Emerging mechanisms and promising approaches in pancreatic cancer metabolism
Wu, H., Fu, M., Wu, M., Cao, Z., Zhang, Q., & Liu, Z. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06930-0 · Cited by 87 · see citing works
Facts and Hopes in Immunotherapy of Pancreatic Cancer
Bockorny, B., Grossman, J. E., & Hidalgo, M. M. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3452 · Cited by 86 · see citing works
Untangling the web of intratumour heterogeneity
Li, Z., Seehawer, M., & Polyák, K. (2022) · Nature Cell Biology · doi:10.1038/s41556-022-00969-x · Cited by 81 · see citing works
Tarannum, M., & Vivero-Escoto, J. L. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114357 · Cited by 76 · see citing works
Mahadevan, K., LeBleu, V., Ramirez, E. V., Chen, Y., Li, B.-R., Sockwell, A. M., Gagea, M., Sugimoto, H., Sthanam, L. K., Tampe, D., et al. (2023) · Developmental Cell · doi:10.1016/j.devcel.2023.07.025 · Cited by 67 · see citing works
Self-citationMYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer
Casacuberta‐Serra, S., González-Larreategui, Í., Capitán-Leo, D., & Soucek, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01907-z · Cited by 80 · see citing works
Obesity and Pancreatic Cancer: Insight into Mechanisms
Eibl, G., & Rozengurt, E. (2021) · Cancers · doi:10.3390/cancers13205067 · Cited by 72 · see citing works
Targeting KRAS: The Elephant in the Room of Epithelial Cancers
Merz, V., Gaule, M., Zecchetto, C., Cavaliere, A., Casalino, S., Pesoni, C., Contarelli, S., Sabbadini, F., Bertolini, M., Mangiameli, D., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.638360 · Cited by 71 · see citing works
Sun, C., Ye, Y., Tan, Z., Liu, Y., Li, Y., Hu, W., Liang, K., Egranov, S. D., Huang, L. A., Zhang, Z., et al. (2023) · Science Advances · doi:10.1126/sciadv.add6995 · Cited by 66 · see citing works
Self-citationKalluri, V. S., Smaglo, B. G., Mahadevan, K. K., Kirtley, M. L., McAndrews, K. M., Mendt, M., Yang, S., Maldonado, A. S., Sugimoto, H., Salvatierra, M. E., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-63718-2 · Cited by 70 · see citing works
Self-citationRole of the tumor microenvironment in cancer hallmarks and targeted therapy (Review)
Naser, R., Fakhoury, I., El‑Fouani, A., Abi‑Habib, R., & El‑Sibai, M. (2022) · International Journal of Oncology · doi:10.3892/ijo.2022.5471 · Cited by 61 · see citing works
Guo, S., Zhang, Q., Guo, Y., Yin, X., Zhang, P., Mao, T., Tian, Z., & Li, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1497026 · Cited by 61 · see citing works
Liu, H., Liang, Z., Cheng, S., Huang, L., Li, W., Zhou, C., Zheng, X., Li, S., Zeng, Z., & Kang, L. (2023) · Advanced Science · doi:10.1002/advs.202203757 · Cited by 60 · see citing works
KRAS mutation: The booster of pancreatic ductal adenocarcinoma transformation and progression
Zhang, Z., Zhang, H., Liao, X., & Tsai, H. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1147676 · Cited by 62 · see citing works
Donahue, K. L., Watkoske, H. R., Kadiyala, P., Du, W., Brown, K. L., Scales, M. K., Elhossiny, A. M., Espinoza, C. E., Opsahl, E. L. L., Griffith, B. D., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0100 · Cited by 58 · see citing works
The Role of Mitochondria in the Chemoresistance of Pancreatic Cancer Cells
Fu, Y., Ricciardiello, F., Yang, G., Qiu, J., Huang, H., Xiao, J., Cao, Z., Zhao, F., Liu, Y., Luo, W., et al. (2021) · Cells · doi:10.3390/cells10030497 · Cited by 57 · see citing works
Self-citationKumarasamy, V. M., Frangou, C. G., Wang, J., Wan, Y., Dynka, A., Rosenheck, H. R., Dey, P., Abel, E. V., Knudsen, E. S., & Witkiewicz, A. K. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-2504 · Cited by 56 · see citing works
Self-citationThe interactive role of inflammatory mediators and metabolic reprogramming in pancreatic cancer
Ohara, Y., Valenzuela, P., & Hussain, S. P. (2022) · Trends in cancer · doi:10.1016/j.trecan.2022.03.004 · Cited by 53 · see citing works
Application of High-Throughput Imaging Mass Cytometry Hyperion in Cancer Research
Rochais, M. L., Hémon, P., Pers, J., & Uguen, A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.859414 · Cited by 53 · see citing works
Mechanisms Governing Immunotherapy Resistance in Pancreatic Ductal Adenocarcinoma
Schmiechen, Z. C., & Stromnes, I. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.613815 · Cited by 53 · see citing works
Colangelo, T., Carbone, A., Mazzarelli, F., Cuttano, R., Dama, E., Nittoli, T., Albanesi, J., Barisciano, G., Forte, N. R., Palumbo, O., et al. (2022) · Cell Death and Differentiation · doi:10.1038/s41418-022-00935-y · Cited by 52 · see citing works
Role of the Tumor Microenvironment in Regulating Pancreatic Cancer Therapy Resistance
Deng, D., Patel, R. H., Chiang, C.-Y., & Hou, P. (2022) · Cells · doi:10.3390/cells11192952 · Cited by 50 · see citing works
Thymic Stromal Lymphopoietin and Cancer: Th2-Dependent and -Independent Mechanisms
Protti, M. P., & Monte, L. B. D. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02088 · Cited by 48 · see citing works
MYC-mediated resistance to trametinib and HCQ in PDAC is overcome by CDK4/6 and lysosomal inhibition
Silvis, M. R., Silva, D., Rohweder, R., Schuman, S. S., Gudipaty, S. A., Truong, A., Yap, J. T., Affolter, K. E., McMahon, M., & Kinsey, C. G. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20221524 · Cited by 47 · see citing works
Impact of KRAS mutation on the tumor microenvironment in colorectal cancer
Zhou, Y., Kuang, Y., Wang, C., Yu, Y., Pan, L., & Hu, X. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.88779 · Cited by 43 · see citing works
Zhong, Z., Yang, K., Li, Y., Zhou, S., Yao, H., Zhao, Y., Huang, Y., Zou, J., Li, Y., Li, J., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216784 · Cited by 40 · see citing works
Self-citationThe role of glycolysis in tumorigenesis: From biological aspects to therapeutic opportunities
Cordani, M., Michetti, F., Zarrabi, A., Zarepour, A., Rumio, C., Strippoli, R., & Marcucci, F. (2024) · Neoplasia · doi:10.1016/j.neo.2024.101076 · Cited by 40 · see citing works
Yu, Y., Jiang, Y., Glandorff, C., & Sun, M. (2024) · Cellular Signalling · doi:10.1016/j.cellsig.2024.111239 · Cited by 39 · see citing works
Ding, T., Liu, C., & Li, Z. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02227-8 · Cited by 44 · see citing works
Zhu, M., Li, S., Cao, X., Rashid, K., & Liu, T. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.11.011 · Cited by 38 · see citing works
Murphy, K. J., Chambers, C. R., Herrmann, D., Timpson, P., & Pereira, B. (2021) · Cancers · doi:10.3390/cancers13143481 · Cited by 38 · see citing works
Cell Lineage Infidelity in PDAC Progression and Therapy Resistance
Malinova, A., Veghini, L., Real, F. X., & Corbo, V. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.795251 · Cited by 35 · see citing works
Targeting methionine metabolism in cancer: opportunities and challenges
Bin, P., Wang, C., Zhang, H., Yan, Y., & Ren, W. (2024) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2024.03.002 · Cited by 36 · see citing works
Oncogenic KRAS triggers metabolic reprogramming in pancreatic ductal adenocarcinoma
Shen, X., Niu, N., & Xue, J. (2022) · Journal of Translational Internal Medicine · doi:10.2478/jtim-2022-0022 · Cited by 34 · see citing works
Dimethyl Fumarate Induces Metabolic Crisie to Suppress Pancreatic Carcinoma
Chen, K., Wu, S., Ye, S., Huang, H., Zhou, Y., Zhou, H., Wu, S., Mao, Y., Shangguan, F., Lan, L., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.617714 · Cited by 34 · see citing works
Intratumour microbiome of pancreatic cancer
Guan, S.-W., Lin, Q., & Yu, H. (2023) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v15.i5.713 · Cited by 33 · see citing works
The Role of Adipokines in Pancreatic Cancer
Wang, Q., Wang, H., Ding, Y., Wan, M., & Xu, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.926230 · Cited by 32 · see citing works
Self-citationImmunosurveillance encounters cancer metabolism
Chuang, Y., Tzeng, S., Ho, P., & Tsai, C. (2024) · EMBO Reports · doi:10.1038/s44319-023-00038-w · Cited by 34 · see citing works
PSAT1 impairs ferroptosis and reduces immunotherapy efficacy via GPX4 hydroxylation
Zheng, P., Hu, Z., Shen, Y., Gu, L., Ouyang, Y., Duan, Y., Ji, G., Dong, B., Lin, Y., Wen, T., et al. (2025) · Nature Chemical Biology · doi:10.1038/s41589-025-01887-3 · Cited by 31 · see citing works
Self-citationMoonlighting Metabolic Enzymes in Cancer: New Perspectives on the Redox Code
Jiang, J., Peng, L., Wang, K., & Huang, C. (2020) · Antioxidants and Redox Signaling · doi:10.1089/ars.2020.8123 · Cited by 31 · see citing works
Tumor Microenvironment in Pancreatic Intraepithelial Neoplasia
Opitz, F. V., Häberle, L., Daum, A., & Esposito, I. (2021) · Cancers · doi:10.3390/cancers13246188 · Cited by 30 · see citing works
Immune vulnerabilities of mutant KRAS in pancreatic cancer
Cheng, N. C., & Vonderheide, R. H. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.07.004 · Cited by 30 · see citing works
Liu, R., Li, J., Liu, L., Wang, W., & Jia, J. (2024) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2024.07.004 · Cited by 31 · see citing works
Self-citationLiang, R., Wu, C., Liu, S., & Zhao, W. (2022) · Drug Delivery · doi:10.1080/10717544.2022.2075986 · Cited by 28 · see citing works
Gurreri, E., Genovese, G., Perelli, L., Agostini, A., Piro, G., Carbone, C., & Tortora, G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119313 · Cited by 27 · see citing works
Self-citationZhang, H., Chen, J., Hu, X., Bai, J., & Yin, T. (2023) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10518 · Cited by 26 · see citing works
Hafezi, S., Saber-Ayad, M. M., & Abdel‐Rahman, W. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910219 · Cited by 26 · see citing works
Dice-XMBD: Deep Learning-Based Cell Segmentation for Imaging Mass Cytometry
Xiao, X., Qiao, Y., Jiao, Y., Fu, N., Yang, W., Wang, L., Yu, R., & Han, J. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.721229 · Cited by 25 · see citing works
Ductal metaplasia in pancreas.
Li, S., & Xie, K. (2022) · Biochimica et biophysica acta. Reviews on cancer · doi:10.1016/j.bbcan.2022.188698 · Cited by 21 · see citing works
Bandi, D. S. R., Sarvesh, S., Farran, B., Nagaraju, G. P., & El‐Rayes, B. F. (2023) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2023.06.006 · Cited by 25 · see citing works
Yang, S. S., Tang, W., Azizian, A., Gaedcke, J., Ohara, Y., Cawley, H., Hanna, N. N., Ghadimi, M. B., Lal, T., Sen, S., et al. (2024) · Carcinogenesis · doi:10.1093/carcin/bgae025 · Cited by 25 · see citing works
Self-citationNeuß, T., Chen, M.-C., Wirges, N., Usluer, S., Oellinger, R., Lier, S., Dudek, M., Madl, T., Jastroch, M., Steiger, K., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-2213 · Cited by 23 · see citing works
Liu, X., Yang, J., Huang, S., Hong, Y., Zhu, Y., Wang, J., Wang, Y., Liang, T., & Bai, X. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.01.023 · Cited by 24 · see citing works
Self-citationPrognostic Biomarker DDOST and Its Correlation With Immune Infiltrates in Hepatocellular Carcinoma
Zhu, C., Xiao, H., Jiang, X., Tong, R., & Guan, J. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2021.819520 · Cited by 24 · see citing works
Fang, Z., Wang, W., Liu, Y., Hua, J., Liang, C., Jiang, L., Zhang, B., Shi, S., Yu, X., Meng, Q., et al. (2023) · Current Oncology · doi:10.3390/curroncol30030228 · Cited by 24 · see citing works
IL-4 and IL-13 Promote Proliferation of Mammary Epithelial Cells through STAT6 and IRS-1
Wu, W.-J., Wang, S., Wu, C., Su, Y., Chiang, C.-Y., Lai, C.-H., Wang, T.-H., Cheng, T., Kuo, J.-Y., Hsu, T., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222112008 · Cited by 23 · see citing works
Chen, P., Ning, Y., Li, H., Su, J.-G., Shen, J.-B., Feng, Q.-C., Jiang, S., Shi, P.-D., & Guo, R.-S. (2023) · Cellular Oncology · doi:10.1007/s13402-023-00852-3 · Cited by 22 · see citing works
Metabolic Constrains Rule Metastasis Progression
Roda, N., Gambino, V., & Giorgio, M. (2020) · Cells · doi:10.3390/cells9092081 · Cited by 21 · see citing works
Shedding Light on the Role of Neurotransmitters in the Microenvironment of Pancreatic Cancer
Liang, Y., Li, H., Gan, Y., & Tu, H. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.688953 · Cited by 22 · see citing works
Zhang, W., Qi, L., Liu, Z., He, S., Wang, C., Wu, Y., Han, L., Liu, Z., Fu, Z., Tu, C., et al. (2023) · MedComm · doi:10.1002/mco2.317 · Cited by 20 · see citing works
Yang, Q., Bariani, M. V., Falahati, A., Khosh, A., Lastra, R. R., Siblini, H., Boyer, T., & Al-Hendy, A. A. (2022) · Cells · doi:10.3390/cells11142160 · Cited by 20 · see citing works
FAK promotes stromal PD-L2 expression associated with poor survival in pancreatic cancer
Davidson, C., Taggart, D., Sims, A. H., Lonergan, D. W., Canel, M., & Serrels, A. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01966-5 · Cited by 20 · see citing works
Hershey, B. J., Barozzi, S., Orsenigo, F., Pompei, S., Iannelli, F., Kamrad, S., Matafora, V., Pisati, F., Calabrese, L., Fragale, G., et al. (2023) · Science Advances · doi:10.1126/sciadv.adh4184 · Cited by 20 · see citing works
Schreyer, D., Neoptolemos, J. P., Barry, S. T., & Bailey, P. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.795735 · Cited by 19 · see citing works
Dutta, P., Castro-Pando, S., Mascaró, M., Riquelme, E. M., Zoltan, M. A., Zacharias, N. M., Gammon, S. T., Piwnica-Worms, D. R., Pagel, M. D., Sen, S., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103722 · Cited by 19 · see citing works
Self-citationZhang, F., Wang, B., Wu, M., Zhang, L., & Ji, M. Q. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1509173 · Cited by 18 · see citing works
Sun, M., Xie, M., Zhang, T., Wang, Y., Huang, W., & Xia, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.739768 · Cited by 18 · see citing works
Self-citationZhang, Z., & Zhang, H. (2021) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.2015321 · Cited by 18 · see citing works
Immuno-oncology-microbiome axis of gastrointestinal malignancy
Lin, Q., Guan, S.-W., & Yu, H. (2023) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v15.i5.757 · Cited by 18 · see citing works
Fujisawa, T., Shimamura, T., Goto, K., Nakagawa, R., Muroyama, R., Ino, Y., Horiuchi, H., Endo, I., Maeda, S., Harihara, Y., et al. (2020) · Cancers · doi:10.3390/cancers12051294 · Cited by 18 · see citing works
LeBleu, V. S., Smaglo, B. G., Mahadevan, K. K., Kirtley, M. L., McAndrews, K. M., Mendt, M. C., Yang, S., Maldonado, A. S., Sugimoto, H., Salvatierra, M. E., et al. (2025) · medRxiv · doi:10.1101/2025.03.03.25322827 · Cited by 18 · see citing works
Self-citationA Novel ZNF304/miR-183-5p/FOXO4 Pathway Regulates Cell Proliferation in Clear Cell Renal Carcinoma
Ren, L., Zeng, B., Zhu, M., Zhao, A., Shi, B., Zhang, H., Wang, D., Gu, J., & Yang, Z. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.710525 · Cited by 17 · see citing works
Zhang, J. H., Darman, L., Hassan, M. S., von Holzen, U. W., & Awasthi, N. (2023) · Oncology Reports · doi:10.3892/or.2023.8643 · Cited by 17 · see citing works
Self-citationMcAndrews, K. M., Paradiso, F., Stalnecker, C. A., Selvanesan, B. C., Thege, F. I., Peng, D. H., Diaz, B. A. M., Sugimoto, H., Patel, S. I., Mahadevan, K. K., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adt5511 · Cited by 16 · see citing works
Self-citationLoss of Interleukin-13-Receptor-Alpha-1 Induces Apoptosis and Promotes EMT in Pancreatic Cancer
Shi, J., Shen, X., Kang, Q., Yang, X., Denzinger, M., Kornmann, M., & Traub, B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073659 · Cited by 15 · see citing works
Conquering oncogenic KRAS and its bypass mechanisms
Hou, P., & Wang, Y. (2022) · Theranostics · doi:10.7150/thno.71260 · Cited by 17 · see citing works
Self-citationRationale for MYC imaging and targeting in pancreatic cancer
Schneider, G., Wirth, M., Keller, U. B., & Saur, D. (2021) · EJNMMI Research · doi:10.1186/s13550-021-00843-1 · Cited by 15 · see citing works
- Authors
- Dey, P., Li, J., Zhang, J., Chaurasiya, S., Strom, A., Wang, H., Liao, W.-T., Cavallaro, F., Denz, P., Bernard, V., Yen, E.-Y., Genovese, G., Gulhati, P., Liu, J., Chakravarti, D., Deng, P., Zhang, T., Carbone, F., Chang, Q., Ying, H., Shang, X., Spring, D. J., Ghosh, B., Putluri, N., Maitra, A., Wang, Y. A., & DePinho, R. A.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- University of Houston (US)
- 3Center for Nuclear Receptor and Cell Signaling, University of Houston, Houston, Texas.
- 1Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
- Roswell Park Comprehensive Cancer Center (US)
- Baylor College of Medicine (US)
- Corresponding author
- DePinho, Ronald A.
- ORCID
- Dey, Prasenjit
- Li, Jun
- Zhang, Jianhua
- Chaurasiya, Surendra
- Wang, Huamin
- Liao, Wen-Ting
- Cavallaro, Frederick
- Denz, Parker
- Bernard, Vincent
- Yen, Er-Yen
- Genovese, Giannicola
- Gulhati, Pat
- Liu, Jielin
- Chakravarti, Deepavali
- Deng, Pingna
- Zhang, Tingxin
- Carbone, Federica
- Chang, Qing
- Ying, Haoqiang
- Shang, Xiaoying
- Spring, Denise J.
- Putluri, Nagireddy
- Maitra, Anirban
- Wang, Y. Alan
- DePinho, Ronald A.
- Venue
- Cancer Discovery
- Published
- 2020-04-01
- Volume
- 10
- Issue
- 4
- Pages
- 608-625
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W3006227213
- Cited by
- 213
- References
- 65
- Citations by year
- 2026: 30 · 2025: 33 · 2024: 33 · 2023: 33 · 2022: 40 · 2021: 36 · 2020: 8
- FWCI
- 10.65
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- MD Anderson (P30CA16672)
- Baylor College of Medicine (P30CA125123)
- CPRIT (RP170005, RP140106170067, 170067)
- NCI (P01 CA117969, R01 CA225955)
- DOD (W81XWH-14-1-0429, K99/R00, 1K99 CA218891-01A1, U24 CA224020, R01 CA218004, R01 CA304969)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Health Sciences › Medicine › Oncology › Cytokine Signaling Pathways and Interactions
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- pancreatic ductal adenocarcinoma, oncogenic KRAS, tumor microenvironment, metabolic reprogramming, glycolysis, c-Myc, STAT6, IL-4, IL-13, Th2 cells, paracrine signaling, tumor stroma
- MeSH terms
- Animals, Humans, Oncogenes, Pancreatic Neoplasms, Transfection, Cytokines, Proto-Oncogene Proteins p21(ras), Mice, Tumor Microenvironment, Cellular Reprogramming
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
